This article has been updated from a previous version .

NEW YORK, May 4 - Canadian population genetics company Xenon Genetics completed its second round of financing, worth $2.6 million, adding to $45 million raised in early April, the company said Friday. 

The additional financing "is going to allow us to continue to expand more quickly," said company spokeswoman Ann David. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.